ENTA Enanta Pharmaceuticals Inc.

53.11
-1.08  -2%
Previous Close 54.19
Open 54.19
Price To Book 2.27
Market Cap 1,047,621,571
Shares 19,725,505
Volume 85,008
Short Ratio
Av. Daily Volume 202,397
Stock charts supplied by TradingView

NewsSee all news

  1. Enanta to Host Conference Call on February 6 at 4:30 p.m. ET to Discuss Financial Results for its Fiscal First Quarter Ended December 31, 2019

    Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating and developing small molecule drugs for viral infections and liver diseases, today announced that it plans to

  2. AbbVie's MAVIRET® now listed on the Newfoundland and Labrador formulary

    MAVIRET® is an 8-week, pan-genotypic treatment for adults and adolescent patients 12 to 18 years of age with chronic hepatitis C virus (HCV) infection without cirrhosis and who are new to treatment.*1 MAVIRET is approved

  3. Enanta to Provide Updates on its R&D Programs and Business Outlook for 2020 during the 38th Annual J.P. Morgan Healthcare Conference

    Presentation and Q&A breakout to be webcast on January 13, 2020 beginning at 2:30 p.m. Pacific Time Several clinical milestones expected in RSV, HBV, and NASH/PBC programs in 2020 New discovery program in

  4. Enanta Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference

    Presentation and Question and Answer Session to be Webcast beginning at 2:30 p.m. PT on January 13, 2020 Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small

  5. Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2019

    Webcast and Conference Call today at 4:30 p.m. ET Initiation of RSVP, a Phase 2b study of EDP-938 in adult outpatients with RSV EDP-297 selected as follow-on FXR agonist with differentiated preclinical

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2b data due 3Q 2020.
EDP-938
Respiratory Syncytial Virus
Phase 2b trial to be initiated 2Q 2020.
EDP-305 ARGON-2
Non-alcoholic steatohepatitis (NASH)
Phase 2 top-line data due 2Q 2020.
EDP-305 INTREPID
Primary biliary cholangitis (PBC)
Approval announced August 3, 2017.
Glecaprevir/Pibrentasvir (G/P)
Hepatitis C virus (HCV)
Approved December 19, 2014.
VIEKIRA PAK
HCV - genotype 1
Approved July 25, 2017.
VIEKIRA PAK - once-daily, fixed-dose formulation through Abbvie
HCV - genotype
Phase 1 data due 1Q 2020.
EDP-514
Hepatitis B virus (HBV)
Phase 1 trial to commence mid-2020.
EDP-297
Non-alcoholic steatohepatitis (NASH)

Latest News

  1. Enanta to Host Conference Call on February 6 at 4:30 p.m. ET to Discuss Financial Results for its Fiscal First Quarter Ended December 31, 2019

    Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating and developing small molecule drugs for viral infections and liver diseases, today announced that it plans to

  2. AbbVie's MAVIRET® now listed on the Newfoundland and Labrador formulary

    MAVIRET® is an 8-week, pan-genotypic treatment for adults and adolescent patients 12 to 18 years of age with chronic hepatitis C virus (HCV) infection without cirrhosis and who are new to treatment.*1 MAVIRET is approved

  3. Enanta to Provide Updates on its R&D Programs and Business Outlook for 2020 during the 38th Annual J.P. Morgan Healthcare Conference

    Presentation and Q&A breakout to be webcast on January 13, 2020 beginning at 2:30 p.m. Pacific Time Several clinical milestones expected in RSV, HBV, and NASH/PBC programs in 2020 New discovery program in

  4. Enanta Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference

    Presentation and Question and Answer Session to be Webcast beginning at 2:30 p.m. PT on January 13, 2020 Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small

  5. Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2019

    Webcast and Conference Call today at 4:30 p.m. ET Initiation of RSVP, a Phase 2b study of EDP-938 in adult outpatients with RSV EDP-297 selected as follow-on FXR agonist with differentiated preclinical

  6. Enanta Pharmaceuticals Announces Poster Presentations at The Liver Meeting® 2019

    Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, announced that three preclinical posters on EDP-305,

  7. Enanta Pharmaceuticals to Host Conference Call on November 21 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2019

    Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating and developing small molecule drugs for viral infections and liver diseases, today announced that it plans to

  8. Enanta Pharmaceuticals to Present at the 2019 Wolfe Research Healthcare Conference

    Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly,

  9. New Data from Enanta's Phase 2a Human Challenge Study of EDP-938 for RSV Demonstrates Highly Statistically Significant Reductions (p<0.001) in Total Symptom Score, Mucus Weight and RSV Viral Load as Measured by RT-PCR Assay and by Plaque Assay

    Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that new data from

  10. AbbVie Receives FDA Approval of MAVYRET® (glecaprevir/pibrentasvir) to Shorten Treatment Duration to Eight Weeks for Treatment-Naïve Patients with Chronic Hepatitis C and Compensated Cirrhosis Across All Genotypes

    NORTH CHICAGO, Ill., Sept. 26, 2019 /PRNewswire/ -- AbbVie (NYSE:ABBV), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted approval

  11. Enanta Announces Positive Results of ARGON-1 Study of its lead FXR Agonist, EDP-305, for the Treatment of NASH

    Primary endpoint, ALT reduction at week 12, was met in the 2.5mg dosing group Key secondary endpoint, reduction in liver fat content as measured by MRI-PDFF at week 12, was met in the 2.5mg dosing

  12. New Data from Enanta's Phase 2a Human Challenge Study of EDP-938 for RSV to be Presented at IDWeek™ 2019

    Late-breaker oral presentation of EDP-938 on October 3 at 2:35 pm ET   Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs